Jacopo Andreose, Angelini Pharma CEO
May 11, 2023 11:01 AM EDT
Deals
R&D

Italy's An­geli­ni Phar­ma teams up with JCR on blood-brain bar­ri­er deal

Paul Schloesser

Associate Editor

An­geli­ni Phar­ma plans to pay Japan­ese phar­ma JCR Phar­ma­ceu­ti­cals more than $500 mil­lion as part of a re­search col­lab­o­ra­tion that fo­cus­es on the blood-brain bar­ri­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times